Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing mri with injected gadobenate dimeglumine or gadoteridol Academic Article uri icon

Overview

MeSH Major

  • Contrast Media
  • Heterocyclic Compounds
  • Kidney Failure, Chronic
  • Magnetic Resonance Imaging
  • Meglumine
  • Nephrogenic Fibrosing Dermopathy
  • Organometallic Compounds

abstract

  • To our knowledge, and consistent with reports in the literature, no association of gadobenate dimeglumine or gadoteridol with unconfounded cases of NSF has yet been established. Study data confirm that both gadoteridol and gadobenate dimeglumine properly belong to the class of GBCAs considered to be associated with the lowest risk of NSF.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.2214/AJR.14.14268

PubMed ID

  • 26295633

Additional Document Info

start page

  • 469

end page

  • 78

volume

  • 205

number

  • 3